Federal Register / Vol. 74, No. 172 / Tuesday, September 8, 2009 / Notices 46227 

additional information, please contact: 

Amy Callaghan, (202) 514–9292, Office 

of Audit, Assessment, and Management, 

Office of Justice Programs, U.S. 

Department of Justice, 810 Seventh 

Street, NW., Washington, DC 20531 or 

Amy.Callaghan@usdoj.gov. 

Written comments and suggestions 

from the public and affected parties 

concerning the proposed collection of 

information are encouraged. Your 

comments should address one or more 

of the following four points: 

—Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

—Evaluate the accuracy of the agency’s 

estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

—Enhance the quality, utility, and 

clarity of the information to be 

collected; and 

—Minimize the burden of the collection 

of information on those who are to 

respond, including through the use of 

appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms 

of information technology, e.g., 

permitting electronic submission of 

responses. 

Overview of This Information 

(1) Type of information collection: 

Information in response to the required 

data elements outlined in the 

solicitation template for programs 

administered by the Office of Justice 

Programs. 

(2) The title of the form/collection: 

Office of Justice Programs solicitation 

template. 

(3) The agency form number, if any, 

and the applicable component of the 

Department sponsoring the collection: 

The Office of Audit, Assessment, and 

Management, Office of Justice Programs, 

U.S. Department of Justice. 

(4) Affected public who will be asked 

or required to respond, as well as a brief 

abstract: State agencies, tribal 

governments, local governments, 

colleges and universities, non-profit 

organizations, for-profit organizations 

and faith-based organizations. The 

purpose of the solicitation template is to 

provide framework to develop programspecific announcements soliciting 

applications for funding. A program 

solicitation outlines the specifics of the 

funding program; describes 

requirements for eligibility; instructs an 

applicant on the necessary components 

of an application under a specific 

program (e.g, project activities and 

timeline, proposed budget); outlines 

program evaluation and performance 

measure; explains selection criteria and 

the review process; and provides 

registration dates, due dates, and 

instructions on how to apply within the 

designated application system. 

(5) An estimate of the total number of 

respondents and the amount of time 

estimated for an average respondent to 

respond/reply: It is estimated that 

information will be collected annually 

from 9,800 applicants, representing 

State agencies, tribal governments, local 

governments, colleges and universities, 

non-profit organizations, and for-profit 

organizations. Annual cost to the 

respondents is based on the number of 

hours involved in preparing and 

submitting a complete application 

package. Public reporting burden for 

this collection of information is 

estimated at up to 30 hours per 

application. The 30-hour estimate is 

based on the amount of time to prepare 

research and evaluation proposals, one 

of the most time intensive types of 

applications solicited by OJP. The 

estimate of burden hours is based on 

OJP’s prior experience with the research 

application submissions process. 

(6) An estimate of the total public 

burden (in hours) associated with the 

collection: The estimated public burden 

associated with this collection is 

294,000 hours. 

If additional information is required 

contact: Mrs. Lynn Bryant, Department 

Clearance Officer, United States 

Department of Justice, Justice 

Management Division, Policy and 

Planning Staff, Suite 1600, 601 D Street, 

NW., Washington, DC 20530. 

Dated: September 1, 2009. 

Lynn Bryant, 

Department Clearance Officer, PRA, U.S. 

Department of Justice. 

[FR Doc. E9–21514 Filed 9–4–09; 8:45 am] 

BILLING CODE 4410–18–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Application 

Pursuant to 21 U.S.C. 958(i), the 

Attorney General shall, prior to issuing 

a registration under this Section to a 

bulk manufacturer of a controlled 

substance in schedule I or II, and prior 

to issuing a regulation under 21 U.S.C. 

952(a)(2) authorizing the importation of 

such a substance, provide 

manufacturers holding registrations for 

the bulk manufacture of the substance 

an opportunity for a hearing. 

Therefore, in accordance with Title 21 

Code of Federal Regulations (CFR), 

1301.34(a), this is notice that on July 16, 

2009, Cerilliant Corporation, 811 

Paloma Drive, Suite A, Round Rock, 

Texas 78665–2402, made application by 

renewal to the Drug Enforcement 

Administration (DEA) to be registered as 

an importer of the basic classes of 

controlled substances listed in 

schedules I and II: 

Drug Schedule 

Cathinone (1235) .......................... I 

Methcathinone (1237) .................. I 

N–Ethylamphetamine (1475) ........ I 

N,N–Dimethylamphetamine 

(1480).

I 

Fenethylline (1503) ....................... I 

Gamma Hydroxybutyric Acid 

(2010).

I 

Ibogaine (7260) ............................ I 

Lysergic acid diethylamide (7315) I 

2,5-Dimethoxy-4-(n)- 

propylthiophenethylamine 

(7348).

I 

Marihuana (7360) ......................... I 

Tetrahydrocannabinols (7370) ..... I 

Mescaline (7381) .......................... I 

3,4,5-Trimethoxyamphetamine 

(7390).

I 

4-Bromo-2,5- 

dimethoxyamphetamine (7391).

I 

4-Bromo-2,5- 

dimethoxyphenethylamine 

(7392).

I 

4-Methyl-2,5- 

dimethoxyamphetamine (7395).

I 

2,5-Dimethoxyamphetamine 

(7396).

I 

3,4-Methylenedioxyamphetamine 

(7400).

I 

3,4-Methylenedioxy-Nethylamphetamine (7404).I 

3,4-Methylenedioxymethamphetamine (7405).I 

4-Methoxyamphetamine (7411) ... I 

Alpha-methyltryptamine (7432) .... I 

Diethyltryptamine (7434) .............. I 

Dimethyltryptamine (7435) ........... I 

Psilocybin (7437) .......................... I 

Psilocyn (7438) ............................. I 

N-Benzylpiperazine (7493) ........... I 

Etorphine (except HCl) (9056) ..... I 

Heroin (9200) ............................... I 

Morphine-N-oxide (9307) ............. I 

Normorphine (9313) ..................... I 

Pholcodine (9314) ........................ I 

Dextromoramide (9613) ............... I 

Dipipanone (9622) ........................ I 

Trimeperidine (9646) .................... I 

Amphetamine (1100) .................... II 

Methamphetamine (1105) ............ II 

Methylphenidate (1724) ................ II 

Amobarbital (2125) ....................... II 

Pentobarbital (2270) ..................... II 

Secobarbital (2315) ...................... II 

Phencyclidine (7471) .................... II 

Phenylacetone (8501) .................. II 

Cocaine (9041) ............................. II 

Codeine (9050) ............................. II 

Dihydrocodeine (9120) ................. II 


jlentini on DSKJ8SOYB1PROD with NOTICES
46228 Federal Register / Vol. 74, No. 172 / Tuesday, September 8, 2009 / Notices 

Drug Schedule 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Benzoylecgonine (9180) ............... II 

Ethylmorphine (9190) ................... II 

Meperidine (9230) ........................ II 

Methadone (9250) ........................ II 

Dextropropoxyphene, bulk (nondosage forms).

(9273) ........................................... II 

Morphine (9300) ........................... II 

Oripavine (9330) ........................... II 

Thebaine (9333) ........................... II 

Levo-alphacetylmethadol (9648) .. II 

Oxymorphone (9652) ................... II 

Poppy Straw Concentrate (9670) II 

Fentanyl (9801) ............................ II 

The company plans to import small 

quantities of the listed controlled 

substances for the manufacture of 

analytical reference standards. 

Any bulk manufacturer who is 

presently, or is applying to be, 

registered with DEA to manufacture 

such basic classes of controlled 

substances may file comments or 

objections to the issuance of the 

proposed registration and may, at the 

same time, file a written request for a 

hearing on such application pursuant to 

21 CFR 1301.43, and in such form as 

prescribed by 21 CFR 1316.47. 

Any such comments or objections 

should be addressed, in quintuplicate, 

to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than October 8, 2009. 

This procedure is to be conducted 

simultaneously with, and independent 

of, the procedures described in 21 CFR 

1301.34(b), (c), (d), (e), and (f). As noted 

in a previous notice published in the 

Federal Register on September 23, 1975, 

(40 FR 43745–46), all applicants for 

registration to import a basic class of 

any controlled substance listed in 

schedule I or II are, and will continue 

to be, required to demonstrate to the 

Deputy Assistant Administrator, Office 

of Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a); 21 U.S.C. 823(a); and 21 

CFR 1301.34(b), (c), (d), (e), and (f) are 

satisfied. 

Dated: August 28, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–21543 Filed 9–4–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Application 

Pursuant to 21 U.S.C. 958(i), the 

Attorney General shall, prior to issuing 

a registration under this Section to a 

bulk manufacturer of a controlled 

substance in schedule I or II and prior 

to issuing a regulation under 21 U.S.C. 

952(a)(2) authorizing the importation of 

such a substance, provide 

manufacturers holding registrations for 

the bulk manufacture of the substance 

an opportunity for a hearing. 

Therefore, in accordance with Title 21 

Code of Federal Regulations (CFR), 

1301.34(a), this is notice that on July 8, 

2009, Clinical Supplies Management, 

Inc., 342 42nd Street South, Fargo, 

North Dakota 58103, made application 

by renewal to the Drug Enforcement 

Administration (DEA) to be registered as 

an importer of Sufentanil (9740), a basic 

class of controlled substance listed in 

schedule II. 

The company plans to import the 

listed controlled substance with the sole 

purpose of packaging, labeling, and 

distributing to customers which are 

qualified clinical sites conducting 

clinical trials under the auspices of an 

FDA-approved clinical study. 

Any bulk manufacturer who is 

presently, or is applying to be, 

registered with DEA to manufacture 

such basic class of controlled substance 

may file comments or objections to the 

issuance of the proposed registration 

and may, at the same time, file a written 

request for a hearing on such 

application pursuant to 21 CFR 1301.43 

and in such form as prescribed by 21 

CFR 1316.47. 

Any such comments or objections 

should be addressed, in quintuplicate, 

to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, VA 22152; and must be 

filed no later than October 8, 2009. 

This procedure is to be conducted 

simultaneously with, and independent 

of, the procedures described in 21 CFR 

1301.34(b), (c), (d), (e) and (f). As noted 

in a previous notice published in the 

Federal Register on September 23, 1975, 

(40 FR 43745–46), all applicants for 

registration to import a basic class of 

any controlled substance in schedule I 

or II are and will continue to be required 

to demonstrate to the Deputy Assistant 

Administrator, Office of Diversion 

Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a); 21 U.S.C. 823(a); and 21 

CFR 1301.34(b), (c), (d), (e), and (f) are 

satisfied. 

Dated: August 28, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–21541 Filed 9–4–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Application 

Pursuant to 21 U.S.C. 958(i), the 

Attorney General shall, prior to issuing 

a registration under this Section to a 

bulk manufacturer of a controlled 

substance in schedule I or II and prior 

to issuing a regulation under 21 U.S.C. 

952(a)(2) authorizing the importation of 

such a substance, provide 

manufacturers holding registrations for 

the bulk manufacture of the substance 

an opportunity for a hearing. 

Therefore, in accordance with Title 21 

Code of Federal Regulations (CFR), 

1301.34(a), this is notice that on July 2, 

2009, GE Healthcare, 3350 North Ridge 

Avenue, Arlington Heights, Illinois 

60004–1412, made application by 

renewal to the Drug Enforcement 

Administration (DEA) to be registered as 

an importer of Cocaine (9041), a basic 

class of controlled substance listed in 

schedule II. 

The company plans to import small 

quantities of ioflupane, in the form of 

three separate analogues of Cocaine, to 

validate production and quality control 

systems, for a reference standard, and 

for producing material for a future 

investigational new drug (IND) 

submission. 

Any bulk manufacturer who is 

presently, or is applying to be, 

registered with DEA to manufacture 

such basic class of controlled substance 

may file comments or objections to the 

issuance of the proposed registration 

and may, at the same time, file a written 

request for a hearing on such 

application pursuant to 21 CFR 1301.43 

and in such form as prescribed by 21 

CFR 1316.47. 

Any such comments or objections 

should be addressed, in quintuplicate, 

to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, VA. 22152; and must be 

filed no later than October 8, 2009. 


jlentini on DSKJ8SOYB1PROD with NOTICES